No Data
No Data
Further Weakness as UroGen Pharma (NASDAQ:URGN) Drops 13% This Week, Taking Five-year Losses to 64%
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript Summary
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $35
Express News | EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target
UroGen Pharma Ltd | 10-Q: Q3 2024 Earnings Report
No Data
No Data